DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,911,795 B2 Schmaus Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,911,795 B2 Schmaus Et Al US00891. 1795B2 (12) United States Patent (10) Patent No.: US 8,911,795 B2 Schmaus et al. (45) Date of Patent: *Dec. 16, 2014 (54) COMPOSITIONS COMPRISING (52) U.S. Cl. DHYDROAVENANTHRAMIDED AND CPC ............. A61O5/006 (2013.01); A61 K 2800/75 CLIMBAZOLEAS COSMETIC AND (2013.01); A61 K31/196 (2013.01); A61 K PHARMACEUTICAL COMPOSITIONS FOR 8/445 (2013.01); A61O 19/00 (2013.01) ALLEVIATING ITCHING USPC ............ 424/640; 514/188: 514/345; 514/563 (58) Field of Classification Search (75) Inventors: Gerhard Schmaus, Höxter (DE); None Joachim Röding, Badenweiler (DE) See application file for complete search history. (73) Assignee: Symrise AG, Holzminden (DE) (56) References Cited U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 4,070,484 A 1/1978 Harita et al. 8,409,552 B2 * 4/2013 Schmaus et al. ................ 424,61 U.S.C. 154(b) by 1390 days. 2003/0161802 A1* 8, 2003 Flammer et al. ............. 424.70.1 This patent is Subject to a terminal dis 2003/0228272 Al 12/2003 Amjad et al. claimer. 2006/0089413 A1* 4/2006 Schmaus et al. .............. 514,563 (21) Appl. No.: 12/095,453 FOREIGN PATENT DOCUMENTS JP 2005187398 7/2005 (22) PCT Filed: Nov. 3, 2006 WO WO-2004O35O15 4/2004 WO WO 2004/047833 * 6, 2004 ........... A61K 31,196 (86). PCT No.: PCT/EP2006/068077 WO WO-2004O47833 6, 2004 WO WO-2006134013 12/2006 S371 (c)(1), WO WO-2006134120 12/2006 (2), (4) Date: Apr. 23, 2009 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2007/062957 Wilbrand, G., “Dealing with Dandruff.” Soap Perfumery and Cos PCT Pub. Date: Jun. 7, 2007 metics, United Trade Press Ltd. London, GB, vol. 72, No. 4, 1999, pp. 79-83, XP009082627, ISSN: 0037-749X, Abstract. (65) Prior Publication Data Wilbrand G., “Vergleichsstudie Ichthyol Pale Versus Zink Pyrithion (Bei Kopfschuppen, Juckreiz, Fettigem Haar). Kosmetische US 2009/0226,537 A1 Sep. 10, 2009 Medizin, Grosse Verlag GMBH, Berlin, DE, vol. 20, No. 5, Nov. 1999, pp. 252-253, XP009082589, ISSN: 1430-4031, Abstract. Related U.S. Application Data * cited by examiner (60) Provisional application No. 60/740,690, filed on Nov. Primary Examiner — Carlos Azpuru 30, 2005. Assistant Examiner — David Browe (74) Attorney, Agent, or Firm — Dilworth & Barrese, LLP (51) Int. Cl. (57) ABSTRACT AOIN 59/6 (2006.01) Compositions comprising dihydroavenanthramide D and A6 IK33/32 (2006.01) climbazole; and, cosmetics or pharmaceutical end products A61O5/00 (2006.01) comprising the compositions, useful for treating skin and/or A6 IK3I/96 (2006.01) hair. A6 IK 8/44 (2006.01) A61O 19/00 (2006.01) 13 Claims, No Drawings US 8,911,795 B2 1. 2 COMPOSITIONS COMPRISING This object is achieved according to the invention by the DHYDROAVENANTHRAMIDED AND provision of a mixture comprising or consisting of CLIMBAZOLE AS COSMETIC AND (a) one or more compounds of Formula 1: PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING Yp CROSS REFERENCE TO RELATED RI O 21 A. APPLICATIONS 10 N N N X.-- H The application claims the benefit of PCT/EP2006/068077 in 2 R2 COOR3 filed on Nov. 3, 2006, and of U.S. Provisional Patent Appli cation 60/740,690 filed on Nov.30, 2005, the disclosures of which are hereby incorporated by reference. where the symbols in the compound or each compound of 15 Formula 1 are defined as follows: m=0, 1, 2 or 3, BACKGROUND OF THE INVENTION p=0, 1 or 2. n=0, 1 or 2, The present invention relates to mixtures of anthranilic where, when n=1 or 2, R' and R in pairs are each H or acid amides and antidandruff agents which can be used espe together are another chemical bond (e.g. in cinnamic acid cially as cosmetic and pharmaceutical compositions for alle derivatives), where, when m=1, 2 or 3, each X independently of the others viating itching. is OH, Oalkyl or Oacyl, WO 2004/047833, on which the present invention is based, and where, when p=1 or 2, each Y independently of the others discloses that certain anthranilic acid amides (of Formula 1) 25 is OH, Oalkyl or Oacyl, and inhibit the substance P-induced release of histamines from R=H or alkyl (especially CHs, linear or branched alkyl mast cells and thus are suitable as cosmetic and pharmaceu chains having 2 to 30 C atoms), R=H also representing the tical compositions for alleviating itching. The compounds of corresponding cosmetically or pharmaceutically acceptable Formula 1 indicated in WO 2004/047833 are also particularly 30 salts and Solvates; preferred for use within the framework of the present inven and tion. (b) one or more antidandruff agents. WO 2004/047833 discloses that the use concentration of a DETAILED DESCRIPTION OF THE INVENTION particular compound of Formula 1 is up to 10 percent by weight, based on the total weight of a ready-to-use cosmetic 35 Formula 1 above thus coversall the compounds of Formula or pharmaceutical end product. In some cases, however, Such 1 from WO 2004/047833 as well as some compounds not high use concentrations seem to be problematic for cosmetic covered by the disclosure of WO 2004/047833. and/or pharmaceutical reasons relating e.g. to formulation Although it is already known from WO 2004/047833 that a technology. cosmetic preparation can contain, in addition to a compound 40 of Formula 1 (with the somewhat narrower definition accord ing to WO 2004/047833), other active compounds for allevi BRIEF SUMMARY OF THE INVENTION ating reddening and itching, WO 2004/047833 does not dis close that the addition of antidandruff agents leads to a synergistic intensification of the action of a compound of The object of the present invention was therefore to provide 45 Formula 1 (with the somewhat broader definition according mixtures active in the alleviation of itching and/or the reduc to the present invention). tion of skin reddening which contain, in addition to one or Although it is known that certain antidandruff agents can more compounds of Formula 1: reduce susceptibility to itching and thereby exert an alleviat ing effect (G. Wilbrand, Kosmetische Medizin Vol.20(5), pp 50 252-253, 1999), there are no disclosures relating to the com 1 bination of antidandruff agents with compounds of Formula Yp 1. Likewise, there are no disclosures relating to the synergis tic interaction of antidandruff agents with compounds of For RI O 1 mula 1. N N N 55 Particularly preferred compounds of Formula 1 for use in X.-- H the mixture according to the invention are those in which: in 21 R 2 COOR 3 n=1 or 2 and the sum p+m-0 and/or p+m-0 and X or Y is selected at least once from the group 60 comprising OH and Oacyl. It is particularly preferable to use a compound of Formula (see below for definitions of substituents and variables), 1 in which: another compound which interacts synergistically with the n=1 compound(s) of Formula 1 so that even low use concentra and tions of the compound(s) of Formula 1 and the other com 65 p+m22. pound are sufficient to produce a good effect in the alleviation with the proviso that X and Y together are selected at least of itching or the reduction of reddening. twice from the group comprising OH and Oacyl. US 8,911,795 B2 3 4 It is also preferable to use a compound of Formula 1 in -continued which: n=1, and also: m=1, 2 or 3, with the proviso that X is selected at least once from the group comprising OH and Oacyl, and/or 10 p=1 or 2, with the proviso that Y is selected at least once from the group MeO comprising OH and Oacyl. If n has the value 1, R' and R are each preferably H, 15 although it is also possible for R' and R together to be another chemical bond. 10 The compound of Formula 1 is preferably selected from the group comprising: 11 HO 25 OH -CCO2H HO OH 30 OCO2H 12 HO OH OCO2H 35 HO N OH 13 MeO 40 OH CO2H MeO H OH 45 MeO 30 CO2H OH HO 50 OH N CO2H 55 CO2H 31 HO OH 60 MeO -OCO2H 65 CO2H HO MeO US 8,911,795 B2 7 8 -continued -continued OH O H N HO O1nS1an C 2 H 51 OH 10 a- 59 OO YO1OYnS)ann)an Y O H NN 15 HO CC 22 HH N OYYXaYa Ya 52 HHOO OO C H HHS O H 2 60 2O HO OH1s-1S-1N 25 OH1s-1S-1N 53 61 O H O OYYOYYSYNYYY1Ye Y 30 N Y YX a Ya Y Y,O Oalax a N H CC HH 22 62 O H HO O H O 54 35 N HO C O2 H N H1s-1S-1NO 40 63 O H O 55 N HO 45 C O2 N OYXa H 64 O H 50 O 56 OH N HO S.CO 55 N 65 O H 57 60 OH Y YX Y. Y. Y. Y.O N OYYSYYa Y C 2 H HO OH N 65 The above illustrations relate essentially to compounds of OOOOO22222 Formula 1 in which n=1. US 8,911,795 B2 9 10 However, the use of compounds of Formula 1 in which n=0 -continued is also frequently preferred, in which case the following defi 27 nition preferably applies: m+p22. with the proviso that at least two of the substituents X and Y are selected from the group comprising OH and Oacyl.
Load more

Recommended publications
  • A Comparison of Clinical Efficacy Between a Basic Shampoo With
    Original Article A Comparison of Clinical Efficacy between a Basic Shampoo with Herbal Extracts Containing Climbazole and Its Similar Sample Containing Piroctone Olamine in the Treatment of Dandruff and Seborrheic Dermatitis Hosein Rastegar, PhD1 Abstract Hamidreza Ahmadi Ashtiani, PhD Background: Dandruff especially with itching and inflammation is a Student2 common complaint among patients in the clinic and its treatment is Mohammad Baghaei, Pharm D3 much challenging. Chemical anti fungal substances used in Saeid Bokaei, PhD4 antidandruff shampoos are common treatments. The aim of this study 5 was to compare the clinical efficacy of two of these anti dandruff Amirhoushang Ehsani, MD substances, climbazole and piroctone olamine in the treatment of Pedram Noormohammadpour, MD5 dandruff and seborrheic dermatitis in shampoos with herbal extracts. 5 Sahar Azizahari, MD Methods: One hundred and twenty men with scalp dandruff of the Ramin Khanmohammad6 same severity, between 20-30 years old and in the same occupational condition in terms of sun exposure or environmental 1. Laboratory Research Centre of Food and pollution were selected and divided randomly into two 60-subject Drug, Ministry of Health and Medical groups. After each shampoo was applied 3 times a week for 5 Educations, Islamic Republic of Iran weeks one in group 1 and the other in group 2, patients were 2. Department of Clinical Biochemistry, assessed for existence of itching and redness of scalp and reduction School of Medical Science, Tarbiat-e- in dandruff and results were compared between two groups. Modarres University, Tehran, Iran and Biochemistry & Nutrition Department of Results: Itching and redness were completely cured in both groups Zanjan Medical University and Institute of after treatment.
    [Show full text]
  • Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007
    Contact Office of Imported Food Safety, Inspection and Safety Division, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare (extension: 2474, 2497, 2498) Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007 August 2008 Department of Food Safety Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare Results of Monitoring and Guidance Based on the Imported Foods Monitoring and Guidance Plan for FY2007 Introduction The total number of foods, additives, equipment, containers and packages, and toys (hereinafter collectively referred to as “foods”) imported to Japan in FY2007 was about 1.80 million, with an imported weight of about 32.3 million tons. According to the Food Balance Sheet for FY 2007 by the Ministry of Agriculture, Forestry and Fisheries, the food self-sufficiency ratio in Japan (food self-sufficiency ratio based on the total caloric value supplied) was estimated at 40%, indicating that, on a calorie basis, approximately 60% of foods consumed in Japan are imported. Regarding the monitoring and guidance conducted by the national government for the purpose of ensuring the safety of foods imported to Japan (hereinafter referred to as “imported foods”), the Imported Foods Monitoring and Guidance Plan for FY2007 (hereinafter referred to as the “Plan”) was developed based on public comments and risk communications, and was conduced in line with the Guidelines for the Implementation of Monitoring and Guidance on Food Sanitation (Notification No. 301 of the Ministry of Labour, Health and Welfare, 2003) under Article 23, paragraph 1 of the Food Sanitation Law (Law No.
    [Show full text]
  • Development and Validation of UV Spectroscopic Method for Estimation of Climbazole in Climbazole Shampoo
    RESEARCH ARTICLE Am. J. PharmTech Res. 2020; 10(01) ISSN: 2249-3387 Journal home page: http://www.ajptr.com/ Development and Validation of UV Spectroscopic Method for Estimation of Climbazole in Climbazole Shampoo Rajashree N. Patil*1, Pratiksha A. Patil1, Swapnil R. Patil2, Amol Sawale2 1.Department of Pharmaceutical Chemistry, Arunamai College of Pharmacy, Mamurabad, North Maharashtra University, Jalgaon (MH) INDIA 425002. 2.Department of Pharmaceutics and Quality Assurance, Vidya Bharati College of Pharmacy, Amravati University, Amravati (MH) INDIA 444602. ABSTRACT To develop and validate simple, rapid, linear, accurate, precise and economical UV Spectroscopic method for estimation of Climbazole in Climbazole shampoo. The drug is freely soluble in organic solvents such as Chloroform and Methanol. The drug was identified in terms of solubility studies and on the basis of melting point done on Melting Point Apparatus of Equiptronics. It showed absorption maxima were determined in Methanol: Water (50:50). The drug obeyed the Beer’s law and showed good correlation of concentration with absorption which reflect in linearity. The UV spectroscopic method was developed for estimation of Climbazole in shampoo dosage form and also validated as per ICH guidelines. The drug is freely soluble in organic solvents such as Methanol, Chloroform. So, the Analytical Grade Methanol: Water is used as a diluent in equal proportion for method. The melting point of Climbazole was found to be 93-94˚C (uncorrected). It showed absorption maxima 256 nm in Methanol: Water (50:50). On the basis of absorption spectrum the working concentration was set on 6µg/ml (PPM). The linearity was observed between 2-10 μg/ml (PPM).
    [Show full text]
  • Climbazole Is a New Potent Inducer of Rat Hepatic Cytochrome P450
    The Journal of Toxicological Sciences, 141 Vol.26, No.3, 141―150, 2001 CLIMBAZOLE IS A NEW POTENT INDUCER OF RAT HEPATIC CYTOCHROME P450 Yasuna KOBAYASHI1, Michiya SUZUKI2, Naomi OHSHIRO1, Takashi SUNAGAWA2, Tadanori SASAKI1, Shogo TOKUYAMA1, Toshinori YAMAMOTO1 and Takemi YOSHIDA2 1Departments of Clinical Pharmacy and 2Biochemical Toxicology, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo142-8555, Japan (Received March 19, 2001; Accepted April 25, 2001) ABSTRACT ― We examined the effect of climbazole on the induction of rat hepatic microsomal cytochrome P450 (P450), and compared the induction potency with other N-substituted azole drugs such as clorimazole. We found that climbazole is found to be a potent inducer of rat hepatic microsomal P450 as clorimazole. Induced level of P450 by climbazole was almost similar in extent to clorimazole when compared with other imidazole drugs in a dose- and time-dependent manner. Parallel to the increase in P450, climbazole increased aminopyrine and erythromycin N-demethylase, ethoxycoumarin O-deethylase, and androstenedione 16β- and 15α/6βhydroxylase activities; however, clorimazole did not induce aminopyrine N-demethylase activity irrespective of its marked increase in P450 content. Immunoblot analyses revealed that climbazole induced CYP2B1, 3A2 and 4A1. The present findings indicate that climbazole is a new potent inducer of hepatic microsomal P450 and drug-metabolizing enzymes like clori- mazole, but it may have some differential mechanism(s) for these enzymes’ induction in rat liver. KEY WORDS: Climbazole, Cytochrome P450, Imidazole, Enzyme induction INTRODUCTION ducing P450 induction. Additionally, we have shown that 1-trityl- and 1-diphenylmethyl-imidazoles induces Cytochrome P450 (P450) constitutes a superfami- CYP2B, whereas 1-benzylimidazole increases both ly of hemeproteins that play a pivotal role in the metab- CYP2B and CYP1A species (Kobayashi et al., 1993).
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,834,409 Ramachandran Et Al
    USOO5834.409A United States Patent (19) 11 Patent Number: 5,834,409 Ramachandran et al. (45) Date of Patent: *Nov. 10, 1998 54 SCALP CARE PRODUCTS CONTAINING 4,867,971 9/1989 Ryan et al. ............................... 424/81 ANTI ITCHING/ANTI IRRITANT AGENTS 4.885,107 12/1989 Wetzel ... 252/106 4,895,727 1/1990 Allen ... ... 424/642 (75) Inventors: Pallassana Narayanier 4,921,170 5/1990 Grollier ................................... 239/304 4,925,659 5/1990 Grollier et al. ........................... 424/78 Ramachandran, Robbinsville; 4997,641 3/1991 Hartnett et al. ... 424/70 Clarence Ralph Robbins, Martinsville; 4,999,195 3/1991 Hayes.............. ... 424/114 Amrit Manilal Patel, Dayton, all of 5,002,761 3/1991 Mueller et al. ... 424/70 N.J. 5,051,250 9/1991 Patel et al. ... ... 424/70 5,091,171 2/1992 Yu et al. ......... 424/642 73) Assignee: Colgate-Palmolive Company, New 5,100,658 3/1992 Bolich, Jr. et al. ... 424/70 York, N.Y. 5,104,646 4/1992 Bolich, Jr. et al. ..... ... 424/70 5,106,609 4/1992 Bolich, Jr. et al. ... 424/70 Notice: This patent issued on a continued pros 5,106,613 4/1992 Hartnett et al. ........................... 424/71 ecution application filed under 37 CFR 5,151,209 9/1992 McCall et al... 252/174.15 1.53(d), and is subject to the twenty year 5,213,716 5/1993 Patel et al. .............................. 252/547 patent term provisions of 35 U.S.C. 5,346,642 9/1994 Patel et al. 252/174.21 5,348,736 9/1994 Patel .........................................
    [Show full text]
  • Topical Antifungals Used for Treatment of Seborrheic Dermatitis
    Journal of Bacteriology & Mycology: Open Access Review Article Open Access Topical antifungals used for treatment of seborrheic dermatitis Abstract Volume 4 Issue 1 - 2017 Seborrheic dermatitis is a common inflammatory condition mainly affecting scalp, Sundeep Chowdhry, Shikha Gupta, Paschal face and other seborrheic sites, characterized by a chronic relapsing course. The mainstay of treatment includes topical therapy comprising antifungals (ketoconazole, D’souza Department of Dermatology, ESI PGIMSR, India ciclopirox olamine) and anti-inflammatory agents along with providing symptomatic relief from itching. Oral antifungals and retinoids are indicated only in the severe, Correspondence: Sundeep Chowdhry, Senior Specialist and recalcitrant cases. The objective of this review is to discuss various topical antifungals Assistant Professor, Department of Dermatology, ESI PGIMSR, available for use in seborrheic dermatitis of scalp, face and flexural areas, discuss their Basaidarapur, New Delhi, India, Tel 919910084482, efficacy and safety profiles from relevant studies available in the literature along with Email [email protected] upcoming novel delivery methods to enhance the efficacy of these drugs. Received: October 28, 2016 | Published: January 06, 2017 Keywords: seborrheic dermatitis, antifungal agents, ketoconazole, ciclopirox Introduction Discussion Seborrheic dermatitis (SD) is a common, chronic inflammatory Treatment considerations disease that affects around 1-3% of the general population in many countries including the U.S., 3-5% of patients consisting of young Treatment for SD should aim for not just achieving remission of adults. The incidence of the disease has two peaks: one in newborn lesions but also to eliminate itching and burning sensation and prevent 6 infants up to three months of age, and the other in adults of around recurrence of the disease.
    [Show full text]
  • Topical Delivery of Climbazole to Mammalian Skin T ⁎ Miguel Paz-Alvareza, , Paul D.A
    International Journal of Pharmaceutics 549 (2018) 317–324 Contents lists available at ScienceDirect International Journal of Pharmaceutics journal homepage: www.elsevier.com/locate/ijpharm Topical delivery of climbazole to mammalian skin T ⁎ Miguel Paz-Alvareza, , Paul D.A. Pudneyb, Jonathan Hadgrafta, Majella E. Lanea a UCL School of Pharmacy, 29-39 Brunswick Square, WC1N 1AX London, UK b Strategic Science Group, Unilever R&D, Colworth Science Park, MK44 1LQ, Sharnbrook, Bedford, UK ARTICLE INFO ABSTRACT Keywords: Dandruff is a common condition, affecting up to half the global population of immunocompetent adults at some In vitro time during their lives and it has been highly correlated with the over-expression of the fungus Malassezia spp. Porcine skin Climbazole (CBZ) is used as an antifungal and preservative agent in many marketed formulations for the Human skin treatment of dandruff. While the efficacy of CBZ in vitro and in vivo has previously been reported, limited in- Finite dose formation has been published about the uptake and deposition of CBZ in the skin. Hence, our aim was to Infinite dose investigate the skin permeation of CBZ as well as the influence of various solvents on CBZ skin delivery. Four Climbazole solvents were selected for the permeability studies of CBZ, namely propylene glycol (PG), octyl salicylate (OSal), Transcutol® P (TC) and polyethylene glycol 200 (PEG). The criteria for selection were based on their wide use as excipients in commercial formulations, their potential to act as skin penetration enhancers and their favourable safety profiles. 1% (w/v) solutions of CBZ were applied under infinite and finite dose conditions using Franz type diffusion cells to human and porcine skin.
    [Show full text]
  • Open Access Article Under the CC by License (
    Molecular and Cellular Endocrinology 524 (2021) 111168 Contents lists available at ScienceDirect Molecular and Cellular Endocrinology journal homepage: www.elsevier.com/locate/mce Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess Katharina R. Beck, Alex Odermatt * Swiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland ARTICLE INFO ABSTRACT Keywords: The syndromes of mineralocorticoid excess describe a heterogeneous group of clinical manifestations leading to Hypertension endocrine hypertension, typically either through direct activation of mineralocorticoid receptors or indirectly by Mineralocorticoid excess impaired pre-receptor enzymatic regulation or through disturbed renal sodium homeostasis. The phenotypes of Azole antifungal these disorders can be caused by inherited gene variants and somatic mutations or may be acquired upon ex­ Adverse drug reaction posures to exogenous substances. Regarding the latter, the symptoms of an acquired mineralocorticoid excess CYP11B 11β-hydroxysteroid dehydrogenase have been reported during treatment with azole antifungal drugs. The current review describes the occurrence of mineralocorticoid excess particularly during the therapy with posaconazole and itraconazole, addresses the underlying mechanisms as well as inter- and intra-individual differences, and proposes a therapeutic drug monitoring strategy for these two azole antifungals. Moreover, other therapeutically used azole antifungals and ongoing efforts to avoid adverse mineralocorticoid effects of azole compounds are shortly discussed. may often be unrecognized. The following sections cover the targets and mechanisms involved in SME, followed by a discussion of recent findings 1. Introduction on azole antifungals causing acquired SME. The management and prevention of hypertension represents an 2. Targets of mineralocorticoid excess and underlying important global health challenge.
    [Show full text]
  • Anti-Fungal Compounds: Emerging Environmental Contaminants
    Anti-fungal compounds: emerging environmental contaminants Azole fungicides are active ingredients in a range of pharmaceutical and personal care products, and are also used in agriculture. This study reviewed 23 September 2016 the sources, presence and risks of these compounds in the environment, finding Issue 471 evidence of toxic effects on aquatic organisms. The researchers provide directions Subscribe to free for future research and warn caution should be exercised until more toxicity data weekly News Alert becomes available. Source: Chen, Z. & Ying, G. Azole fungicides are used to treat fungal infections in agriculture and human (2015). Occurrence, fate and medicine. Usually administered in the form of tablets and ointments, azole fungicides can ecological risk of five typical also be found in common household products, from shampoo and soap to toothpaste and azole fungicides as therapeutic shower gel. Climbazole, which is used in anti-dandruff shampoos and anti-ageing creams, is and personal care products in reportedly used in Europe at a rate of 100–1 000 tonnes per year1. the environment: A review. Environment International, Over the past 10 years, these compounds have emerged as a new class of environmental 84: 142–153. DOI: 10.1016/ pollutants. After use, they are flushed into wastewater treatment plants (WWTPs) and j.envint.2015.07.022. released into rivers where they may have adverse effects on non-target organisms. They are mainly emitted via hospital and municipal wastewater treatment plants. Contact: [email protected], This study investigated the occurrence, life cycle in the environment and toxic effects of the [email protected] five most commonly used azole fungicides: climbazole, clotrimazole, ketoconazole, Read more about: miconazole and fluconazole (most of which are authorised in the EU for use in either human or veterinary medicines and none of which is approved as an active substance to be used in Chemicals, Risk plant-protection products).
    [Show full text]
  • Seborrheic Dermatitis and Its Relationship with Malassezia Spp
    REVIEW Seborrheic dermatitis and its relationship with Malassezia spp Manuel Alejandro Salamanca-Córdoba†,1,2, Carolina Alexandra Zambrano-Pérez2,3, Carlos Mejía-Arbeláez2,4, Adriana Motta5, Pedro Jiménez6, Silvia Restrepo-Restrepo7, Adriana Marcela Celis-Ramírez1,8* Abstract Seborrheic dermatitis (SD) is a chronic inflammatory disease that that is difficult to manage and with a high impact on the individual’s quality of life. Besides, it is a multifactorial entity that typically occurs as an inflammatory response toMalassezia species, along with specific triggers that contribute to its pathophysiology. Sin- ce the primary underlying pathogenic mechanisms include Malassezia proliferation and skin inflammation, the most common treatment includes topical antifungal keratolytics and anti-inflammatory agents. However, the consequences of eliminating the yeast population from the skin, the resistance profiles ofMalassezia spp. and the effectivity among different groups of medications are unknown. Thus, in this review, we summarize the current knowledge on the disease´s pathophysio- logy and the role of Malassezia sp. on it, as well as, the different antifungal treatment alternatives, including topical and oral treatment in the management of SD. Key words: seborrheic dermatitis, Malassezia, pathogenic role, treatment. Dermatitis seborreica y su relación con Malassezia spp Resumen La dermatitis seborreica (DS) es una enfermedad inflamatoria crónica, con un elevado impacto en la calidad de vida del individuo. Además, DS es una entidad multifactorial que ocurre como respuesta inflamatoria a las levaduras del género Malassezia spp., junto con factores desencadenantes que contribuyen a la fisio- patología de la enfermedad. Dado que el mecanismo patogénico principal involucra la proliferación e inflamación generada por Malassezia spp., el tratamiento más usado son los agentes tópicos antifúngicos y antiinflamatorios.
    [Show full text]
  • Clinical Evaluation of Herbal Active Enriched Shampoo in Anti Dandruff Treatment
    Theranostics of Respiratory L UPINE PUBLISHERS & Skin Diseases Open Access DOI: 10.32474/TRSD.2018.01.000105 ISSN: 2644-1306 Research Article Clinical Evaluation of Herbal Active Enriched Shampoo in Anti Dandruff Treatment Sudhir Sawarkar1*, Vinay Deshmukh2, Sankar Jayaganesh1 and Ovureddiar Perumal 1Dabur Research & Development, International Business Development, United Arab Emirates 2Sarkone Life sciences, United Arab Emirates Received: May 26, 2018; Published: June 07, 2018 *Corresponding author: Dr. Sudhir Sawarkar, Dabur Research & Development, International Business Development, Dubai, United Arab Emirates, P.O.Box. 6399 Abstract The human scalp is susceptible to microbial build-up if not thoroughly and frequently washed with the appropriate cleansing agents such as shampoos. Natural oils are presented in our scalp and it called as a sebum and it is a fuel/food for the dandruff-causing microbe. Malassezia feeds off these oils, breaking it down into by products, including oleic acid; formation of oleic acid is a starting/ kick point of dandruff. Approximately 50% people in the world sensitive to the oleic acid and affected by the dandruff. Overall clinical study results revealed that usage of tested anti-dandruff shampoo is effective and significantly reduce the dandruff fungi in Analogue Scale (VAS). The average response of Visual Analogue Scale for visit1 and visit 5 was 6.287 and 0.350 respectively. The scalp. Efficacy was analyzed with changes in the intensity of dandruff over 6 weeks from baseline to treatment visits using Visual average response/changes of Visual Analogue Scale score for Visit1 is 100.00 and Visit 2 having the score of 74.360; Visit 3 having the 47.924, Visit 4 having the score of 19.453 and Visit 5 was having the score of 5.567.
    [Show full text]
  • Narshana and Ravikumar, IJPSR, 2018; Vol. 9(2): 417- 431. E-ISSN: 0975-8232; P-ISSN: 2320-5148
    Narshana and Ravikumar, IJPSR, 2018; Vol. 9(2): 417- 431. E-ISSN: 0975-8232; P-ISSN: 2320-5148 IJPSR (2018), Volume 9, Issue 2 (Review Article) Received on 14 May, 2017; received in revised form, 22 July, 2017; accepted, 25 July, 2017; published 01 February, 2018 AN OVERVIEW OF DANDRUFF AND NOVEL FORMULATIONS AS A TREATMENT STRATEGY M. Narshana*and P. Ravikumar Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (West), Mumbai - 400058, Maharashtra, India. Keywords: ABSTRACT: This review gives an insight of the scalp condition- Liposomes, Solid lipid dandruff which affects more than 50% of the human population. nanoparticles, Malassezia, Malassezia furfur is reported as the main cause of dandruff. This article Anti- dandruff agents, Novel aims at investigating other causes of dandruff which include microbial formulations, Silver nanoparticles and non - microbial factors. These factors have been explained in this Correspondence to Author: article. It also highlights the various treatment options and newer Ms. M. Narshana formulations. Various active agents like anti- fungal agents, keratolytic M. Pharm, agents and anti - proliferative agents that are used against dandruff, along Dr. Bhanuben Nanavati College with their mechanisms of action are covered in this article. Conventional of Pharmacy, Gate No.1, Mithibai formulations like Shampoos, creams and lotions have their own set of College Campus, Vaikunthlal Mehta advantages and limitations. To overcome the disadvantages and prolong Road, Vile Parle (West), Mumbai - 400056, Maharashtra, India. the release of actives, novel formulations like Liposomes, Niosomes, Solid lipid nanoparticles, Nanolipid carriers and Silver nanoparticles are E-mail: [email protected] being developed. Novel delivery systems have been successfully used for pharmaceutical formulations and they can prove to be a promising delivery system for scalp treatment too.
    [Show full text]